Chronic tophaceous gout: emphasis on lifestyle modification and treatment adherence
https://doi.org/10.17650/1818-8338-2025-19-2-K743
Abstract
Aim. To illustrate a comprehensive approach to management of a patient with long-standing generalized tophaceous gout, taking into account concomitant comorbidities, as well as to analyze the factors influencing adherence to therapy and lifestyle modification.
Material and methods. Patient N., 54 years old, with a 16-year history of gout, multiple tophi, hyperuricemia, stage C2 chronic kidney disease (glomerular filtration rate 69.8 ml/min/1.73 m2), dyslipidemia, grade 1 obesity, and nephrolithiasis. A comprehensive clinical, laboratory, and instrumental diagnostic evaluation was performed, and the nature of joint changes and the comorbidity degree were verified. Specialists prescribed uric acid-lowering therapy with febuxostat (80 mg/day), along with preventing therapy for recurrent gouty arthritis using colchicine (0.5 mg/day), rosuvastatin (10 mg/day), and measures for dietary and weight correction.
Results. Against the background of the ongoing therapy, a sustained clinical and laboratory effect was achieved over four months: serum uric acid levels decreased to 282 µmol/L, no arthritis recurrences were recorded, and positive dynamics in the volume of tophaceous infiltration were observed. The patient demonstrates a high level of compliance, following the treatment regimen and recommendations on diet and physical activity.
Conclusion. Modern management of gout requires a comprehensive approach that includes pharmacotherapy and lifestyle modification. However, in practice, only a few patients achieve target uric acid levels, indicating the need to strengthen prevention, educational programs, and improve adherence to treatment.
About the Authors
A. A. Klimenko
N.I. Pirogov National Research Medical University, Ministry of Health of Russia; N.I. Pirogov City Clinical Hospital No. 1, Moscow Healthcare Department
Russian Federation
Russian Federation
Alesya Alexandrovna Klimenko
1 Ostrovityanova St., Moscow 117513, Russia; 8 Leninskiy Prospekt, Moscow 117049, Russia
A. A. Kondrashov
N.I. Pirogov National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Ostrovityanova St., Moscow 117513, Russia
N. A. Shostak
N.I. Pirogov National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Ostrovityanova St., Moscow 117513, Russia
References
1. Safiri S., Kolahi A.A., Cross M. et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol 2020;72(11):1916–27. DOI: 10.1002/art.41404
2. Amatucci A.J., Padnick-Silver L., LaMoreaux B., Bulbin D.H. Comparison between early-onset and common gout: a systematic literature review. Rheumatol Ther 2023;10(4):809–23. DOI: 10.1007/s40744-023-00565-x
3. Nuki G., Simkin P.A. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006;8(Suppl 1):S1. DOI: 10.1186/ar1906
4. Клименко А.А., Шостак Н.А., Андрияшкина Д.А., Кондрашов А.А. Подагра: возможности оптимизации лечения. Клиницист 2024;18(3):69–78. DOI: 10.17650/1818-8338-2024-18-3-K723 Klimenko A.A., Shostak N.A., Andriyashkina D.A., Kondrashov A.A. Gout: possibilities of treatment optimization. Klinicist = The Clinician 2024;18(3):69–78. (In Russ.). DOI: 10.17650/1818-8338-2024-18-3-K723
5. Neupane D., Lageju N., Jaiswal L.S. et al. Tophaceous gout. Clin Case Rep 2024;12(6):e9033. DOI: 10.1002/ccr3.9033
6. Wang Y., Ma R., Ruan B., Guo M. Vocal cord gout nodules: a case report and review of the literature. Ear Nose Throat J 2025; 104(1_suppl):287S–90S. DOI: 10.1177/01455613221137225
7. Han X., Zhang Y. Nasal tophi. Ann Rheum Dis 2024;83(7):957. DOI: 10.1136/ard-2023-225246
8. Kalfoutzou A., Doumana A., Karamolegkou A.I. et al. DRESSed for distress: a case of allopurinol-induced DRESS syndrome. Folia Med (Plovdiv) 2024;66(6):929–34. DOI: 10.3897/folmed.66.e126615
9. Yang W., Yang C. Septic arthritis caused by gout progressed to sepsis and hemophagocytic syndrome. Heliyon 2024;10(9):e30583. DOI: 10.1016/j.heliyon.2024.e30583
10. Li X., Song X., Pan Z., Wei P. Surgical treatment of ulcerating tophaceous gout. Asian J Surg 2024;47(6):2839–40. DOI: 10.1016/j.asjsur.2024.02.088
11. Barbon D.A., Williams T.P., Hulse H.B., Hansford B.G. Primary lymphoma of bone of the little finger: a case report and review of the literature. Skeletal Radiol 2024;53(8):1645–50. DOI: 10.1007/s00256-024-04576-9
12. Bachmann M., Zachariassen K., Pauli C. et al. Ultrasound-guided synovial biopsy. Praxis (Bern 1994) 2024;113(11–12):318–20. (in German). DOI: 10.23785/PRAXIS.2024.11.006
13. Dalbeth N., Gosling A.L., Gaffo A., Abhishek A. Gout. Lancet 2021;397(10287):1843–55. DOI: 10.1016/S0140-6736(21)00569-9
14. Sarma P., Das D., Deka P., Deka A.C. Subconjunctival urate crystals: a case report. Cornea 2010;29(7):830–2. DOI: 10.1097/ICO.0b013e3181c58ecb
15. Iacobellis G. A rare and asymptomatic case of mitral valve tophus associated with severe gouty tophaceous arthritis. J Endocrinol Invest 2004;27(4):965–6. DOI: 10.1007/BF03347542
16. Neogi T. Clinical practice. Gout. N Engl J Med 2011;364(5):443–52. DOI: 10.1056/NEJMcp1001124
17. Подагра. Клинические рекомендации РФ 2013–2017. Доступно по: https://diseases.medelement.com/?searched_data=diseases&q=подагра&mq=&tq=&diseases_filter_type=list&diseases_content_type=9§ion_medicine=0&category_mkb=0&parent_category_mkb=0 Gout.
18. FitzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020;72(6):744–60. DOI: 10.1002/acr.24180
19. Gwinnutt J.M., Wieczorek M., Rodriguez-Carrio J. et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses. RMD Open 2022;8(2):e002167. DOI: 10.1136/rmdopen-2021-002167
20. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707
21. Dehlin M., Jacobsson L., Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16(7):380–90. DOI: 10.1038/s41584-020-0441-1
22. Bardin T., Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017;15(1):123. DOI: 10.1186/s12916-017-0890-9
23. Zhang Y., Chen C., Choi H. et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012;71(9):1448–53. DOI: 10.1136/annrheumdis-2011-201215
24. Holland R., McGill N.W. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J 2015;45(2):189–94. DOI: 10.1111/imj.12661
25. Gibson T., Kilbourn K., Horner I., Simmonds H.A. Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis 1979;38(1):31–5. DOI: 10.1136/ard.38.1.31
26. Nguyen U.D., Zhang Y., Louie-Gao Q. et al. Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy. Arthritis Care Res (Hoboken) 2017;69(4):561–6. DOI: 10.1002/acr.22954
27. Петрова М.С., Шемеровская Т.Г., Мазуров В.И. Актуальные проблемы лечения подагры. Вестник Санкт-Петербургской медицинской академии последипломного образования 2011;3(1):75–9. Petrova M.S., Shemerovskaya T.G., Mazurov V.I. Actual problems of gout treatment. Vestnik Sankt-Peterburgskoy meditsinskoy akademii poslediplomnogo obrazovaniya = Bulletin of the Saint Petersburg Medical Academy of Postgraduate Education 2011;3(1):75–9. (In Russ.).
28. Lunzer R., Delle-Karth G., Zeitlinger M. et al. Colchicine – Phoenix from the ashes. Wien Klin Wochenschr 2025;137(Suppl 1): 1–33. (In German). DOI: 10.1007/s00508-024-02490-7
29. Banco D., Mustehsan M., Shah B. Update on the role of colchicine in cardiovascular disease. Curr Cardiol Rep 2024;26(4):191–8. DOI: 10.1007/s11886-024-02026-5
30. Leung Y.Y., Yao Hui L.L., Kraus V.B. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45(3):341–50. DOI: 10.1016/j.semarthrit.2015.06.013
31. Alberts B., Johnson A., Lewis J. et al. Molecular biology of the cell. 6th ed. New York: Garland Science, 2014. 1464 p.
32. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008;10(3):218–27. DOI: 10.1007/s11926-008-0036-3
33. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707
34. Schlesinger N., Pillinger M.H., Lipsky P.E. Knowledge of and stated adherence to the 2020 American College of Rheumatology guideline for gout management: results of a survey of US rheumatologists. J Rheumatol 2025;52(1):77–86. DOI: 10.3899/jrheum.2023-0981
35. Елисеев М.С., Чикина М.Н., Желябина О.В. и др. Эффективность и безопасность длительного приема различных доз колхицина у пациентов с подагрой. Научнопрактическая ревматология 2025;63(2):197–201. DOI: 10.47360/1995-4484-2025-197-201
36. Зверев Я.Ф., Брюханов В.М. Современный взгляд на механизмы развития уратного нефролитиаза. Клиническая нефрология 2015;(5–6):39–47. Zverev Ya.F., Bryukhanov V.M. Modern view on mechanisms of uric acid nephrolithiasis. Klinicheskaya nefrologiya = Clinical Nephrology 2015;(5–6):39–47. (In Russ.).
37. Аляев Ю.Г., Руденко В.И. Современные аспекты медикаментозного лечения пациентов с мочекаменной болезнью. Эффективная фармакотерапия 2016;(41):10–5. Alyaev Yu.G., Rudenko V.I. Modern aspects of drug treatment of patients with kidney stone disease. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2016;(41):10–5.
Review
For citations:
Klimenko A.A., Kondrashov A.A., Shostak N.A. Chronic tophaceous gout: emphasis on lifestyle modification and treatment adherence. The Clinician. 2025;19(2):39-46. (In Russ.) https://doi.org/10.17650/1818-8338-2025-19-2-K743
Views:
12
Email this article 